<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10533">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654147</url>
  </required_header>
  <id_info>
    <org_study_id>A009</org_study_id>
    <nct_id>NCT00654147</nct_id>
  </id_info>
  <brief_title>Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects</brief_title>
  <acronym>HIV</acronym>
  <official_title>A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margaret A. Fischl, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, open-label pilot study to assess virologic suppression and
      immunologic recovery associated with a two-drug antiretroviral regimen of Raltegravir and
      the protease inhibitor lopinavir/ritonavir (LPV/r) and a three drug regimen with Raltegravir
      and two nRTIs (emtricitabine/tenofovir) in HIV-1 infected treatment-naïve subjects.

      Immunology Substudy added to determine the kinetics of recovery of CD4 T cells and
      subpopulations (regulatory T cell [T regs], TH-17 and TH1) after treatment initiation with
      Raltegravir based regimens and their relationship with functional CD8 T cells and if
      Raltegravir containing therapies leads to decreases in markers of gut microbial
      translocation and of cellular and soluble markers of immune activation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A009 is a prospective, randomized, open-label pilot study to assess virologic suppression
      and immune recovery rates associated with a two-drug potent antiretroviral regimen of
      raltegravir and the protease inhibitor lopinavir/ritonavir and a three-drug regimen with
      raltegravir and two nRTIs (emtricitabine/tenofovir) in treatment-naïve subjects.

      HIV-1-infected subjects who are antiretroviral drug-naïve and have plasma HIV-1 RNA levels
      ≥5000 copies/ml obtained within 30 days prior to study entry will be randomized 1:1 to
      Raltegravir 400 mg BID + LPV 400 mg/RTV 100 mg BID (Arm A) or Raltegravir 400 mg BID + FTC
      200 mg/TDF 300 mg QD (Arm B).

      Subjects will have measurements of HIV-1 RNA and CD4+ and CD8+ T-cell counts at pre-entry
      and entry. The average of these measurements will be used to establish their baseline
      values. Following entry, subjects will have plasma HIV-1 RNA samples drawn at days 2, 4, 8
      and at weeks 2, 4, 8, 16, 24, 32, 40 and 48 and at virologic failure. CD38 expression on
      CD4+/CD8+ cells and CD38/HLA-DR activation antigen on CD4+ and CD8+ cells and subsets T-cell
      percentage will be done at entry, day 8 and weeks 4, 8, 24 and at virologic failure by
      advanced flow cytometry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Confirmed Virologic Failure</measure>
    <time_frame>weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to confirmed viologic failure at 24 weeks (up to 48 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Virologic Failure</measure>
    <time_frame>week 24 (up to 48 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to virologic failure at week 24 (up to 48 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Medication Toxicity-related Discontinuation .</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>grade 3 and grade 4 symptoms and laboratory study treatment limiting toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weeks to HIV-1 RNA &lt;200 Copies/ml</measure>
    <time_frame>from date of treatment start to first week documented viral suppression</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to viral suppression noted as week on study treatment to attain HIV-1 RNA &lt; 200 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline CD4+ and CD8+ Cell Counts</measure>
    <time_frame>Baseline, Weeks 16 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean change in CD4+ and CD8+ T-lymphocytes counts from baseline (defined as the average of pre-entry and entry values) at weeks 16 and 24 in the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Medication Tolerability</measure>
    <time_frame>date started study treatment to first week documented change study treatment up to week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>study treatment tolerability as measured by number of subjects receiving study treatment who either discontinued or changed any component of study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir &amp; Lopinavir/ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir &amp; emtricitabine/tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir &amp; Lopinavir/ritonavir</intervention_name>
    <description>Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor</description>
    <arm_group_label>Raltegravir &amp; Lopinavir/ritonavir</arm_group_label>
    <other_name>Isentress</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir and emtricitabine/tenofovir</intervention_name>
    <description>Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors</description>
    <arm_group_label>Raltegravir &amp; emtricitabine/tenofovir</arm_group_label>
    <other_name>Isentress</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV Infection

          -  Genotypic resistance without major resistance mutations within 30 days

          -  Antiretroviral drug-naïve

          -  Screening HIV-1 RNA ≥5000

          -  Women of reproductive potential

          -  Negative pregnancy test within 48 hours

        Exclusion Criteria:

          -  Acute or recent HIV-1 infection

          -  Currently breast feeding

          -  Use of immunomodulators

          -  Evidence of major resistance mutations

          -  HBsAg positive

          -  Acute hepatitis of any etiology or clinically significant liver disease

          -  Current imprisonment or involuntary incarceration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret A Fischl, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami AIDS Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami AIDS Clinical Research Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 11, 2015</lastchanged_date>
  <firstreceived_date>April 2, 2008</firstreceived_date>
  <firstreceived_results_date>January 20, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Margaret A. Fischl, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine, Director AIDS Clinical Research Unit</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral therapy naive</keyword>
  <keyword>Integrase inhibitor</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>treatment naïve</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Integrase Inhibitors</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomly assigned to receive one of two regimens Raltegravir (Isentress, Merck &amp; Company) 400 mg twice daily with either Lopinavir/ritonavir (Kaletra, Abbott Laboratories) 200 mg/100 mg twice daily or with emtricitabine/tenofovir (Truvada, Gilead Sciences) 200 mg/100 mg twice daily.</recruitment_details>
      <pre_assignment_details>Participants with acute or recent HIV-1 infection, major resistance-associated mutation on any genotype performed at any time prior to study entry, serious illness requiring systemic treatment and/or hospitalization within 7 days of study entry, HBsAg positivity, acute hepatitis of any etiology, clinically significant liver disease were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
          <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
          <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
          <description>Raltegravir 400 mg tablet every 12 hours for 48 &amp; Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
          <description>Raltegravir 400 mg tablet every 12 hours for 48 weeks &amp; emtricitabine 200mg/ tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Confirmed Virologic Failure</title>
        <description>time to confirmed viologic failure at 24 weeks (up to 48 weeks)</description>
        <time_frame>weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>descriptive</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
            <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
            <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Confirmed Virologic Failure</title>
            <description>time to confirmed viologic failure at 24 weeks (up to 48 weeks)</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28" lower_limit="25" upper_limit="56"/>
                  <measurement group_id="O2" value="29" lower_limit="21" upper_limit="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Medication Toxicity-related Discontinuation .</title>
        <description>grade 3 and grade 4 symptoms and laboratory study treatment limiting toxicity</description>
        <time_frame>48 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
            <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
            <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Study Medication Toxicity-related Discontinuation .</title>
            <description>grade 3 and grade 4 symptoms and laboratory study treatment limiting toxicity</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weeks to HIV-1 RNA &lt;200 Copies/ml</title>
        <description>time to viral suppression noted as week on study treatment to attain HIV-1 RNA &lt; 200 copies/ml</description>
        <time_frame>from date of treatment start to first week documented viral suppression</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
            <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
            <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Weeks to HIV-1 RNA &lt;200 Copies/ml</title>
            <description>time to viral suppression noted as week on study treatment to attain HIV-1 RNA &lt; 200 copies/ml</description>
            <units>week to viral supresssion</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>week to &lt;200 Copies/ml</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28" lower_limit="14" upper_limit="56"/>
                  <measurement group_id="O2" value="28" lower_limit="14" upper_limit="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>week to &lt;50 Copies/ml</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56" lower_limit="28" upper_limit="108"/>
                  <measurement group_id="O2" value="56" lower_limit="28" upper_limit="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline CD4+ and CD8+ Cell Counts</title>
        <description>mean change in CD4+ and CD8+ T-lymphocytes counts from baseline (defined as the average of pre-entry and entry values) at weeks 16 and 24 in the two treatment arms</description>
        <time_frame>Baseline, Weeks 16 and 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Change from baseline compared between arms using repeated measures analysis of covariance. Linear mixed models used to accomplish these analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
            <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
            <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline CD4+ and CD8+ Cell Counts</title>
            <description>mean change in CD4+ and CD8+ T-lymphocytes counts from baseline (defined as the average of pre-entry and entry values) at weeks 16 and 24 in the two treatment arms</description>
            <units>cells/mm3</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>week 16 CD4 cells</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="516.34" spread="76.52"/>
                  <measurement group_id="O2" value="452.11" spread="92.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>week 24 CD4 cells</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="521.31" spread="76.52"/>
                  <measurement group_id="O2" value="482.36" spread="93.32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Medication Tolerability</title>
        <description>study treatment tolerability as measured by number of subjects receiving study treatment who either discontinued or changed any component of study treatment</description>
        <time_frame>date started study treatment to first week documented change study treatment up to week 48</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
            <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
            <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Study Medication Tolerability</title>
            <description>study treatment tolerability as measured by number of subjects receiving study treatment who either discontinued or changed any component of study treatment</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Virologic Failure</title>
        <description>time to virologic failure at week 24 (up to 48 weeks)</description>
        <time_frame>week 24 (up to 48 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
            <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
            <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Virologic Failure</title>
            <description>time to virologic failure at week 24 (up to 48 weeks)</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.2296" spread="0.1596"/>
                  <measurement group_id="O2" value="2.9952" spread="0.1812"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir &amp; Lopinavir/Ritonavir</title>
          <description>Raltegravir 400 mg tablet and Lopinavir/ritonavir 400 mg/100 mg capsules every 12 hours for 48 weeks
Raltegravir and Lopinavir/ritonavir: 400 mg BID for 48 weeks 400mg/100 mg BID for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Raltegravir &amp; Emtricitabine/Tenofovir</title>
          <description>Raltegravir 400 mg tablet every 12 hours &amp; emtricitabine 200mg/tenofovir 300 mg tab once daily for 48 weeks
Raltegravir, emtricitabine, tenofovir: 400 mg BID for 48 weeks 200 mg QD for 48 weeks 300 mg QD for 48</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>trigylcerides</sub_title>
                <description>grade 3 or greater elevation in fasting blood triglycerides</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Total bilirubin</sub_title>
                <description>grade 3 or greater elevation in total bilirubin</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study with 44 subjects and generalization f results is limited by the small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director AIDS Clinical Research Unit</name_or_title>
      <organization>University of Miami School of Medicine</organization>
      <phone>305-243-3838</phone>
      <email>mfischl@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
